首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >All-trans retinoic acid mitigates methotrexate-induced liver injury in rats; relevance of retinoic acid signaling pathway
【24h】

All-trans retinoic acid mitigates methotrexate-induced liver injury in rats; relevance of retinoic acid signaling pathway

机译:全反式维甲酸可减轻甲氨蝶呤引起的大鼠肝损伤;视黄酸信号通路的相关性

获取原文
获取原文并翻译 | 示例
           

摘要

Methotrexate (MTX) is a widely used drug for treatment of rheumatic and autoimmune diseases as well as different types of cancer. One of the major side effects of MTX is hepatotoxicity. Retinoid receptors, including retinoid X receptor (RXR), and retinoic acid receptor (RAR) are vitamin A receptors that are highly expressed in the liver and regulate important physiological processes through regulation of different genes. In this study, we investigated the effect of MTX on RXR-alpha and RAR-alpha expression in the liver and the potential protective effects of all-trans retinoic acid (ATRA) in MTX-induced hepatotoxicity. Rats were randomly divided into five groups: The rates were treated with saline, DMSO, MTX (20 mg/kg/IP; single dose), ATRA (7.5 mg/kg/day, I.P), or MTX and ATRA. Rats were killed 24 h after the last ATRA injection. The liver tissues were dissected out, weighed, and subjected to histological, immunohistochemical, and biochemical examinations. Our results demonstrated that treatment with MTX resulted in significant decrease in reduced glutathione (GSH) content and superoxide dismutase (SOD) activity, with concomitant increase in ALT, AST, and MDA levels. In addition, MTX markedly downregulated the expression of both RXR-alpha and RAR-alpha, and changed the appearance of RXR-alpha to be very small speckled droplets. Treatment with ATRA significantly ameliorated MTX-induced effects on GSH, ALT, and MDA. Moreover, ATRA administration increased the expression and nuclear translocation of RXR-alpha in rat hepatocytes. In conclusion, our study revealed, for the first time, that retinoid receptors may play an important role in the MTX-induced hepatotoxicity.
机译:甲氨蝶呤(MTX)是一种广泛用于治疗风湿性和自身免疫性疾病以及不同类型癌症的药物。 MTX的主要副作用之一是肝毒性。维甲酸受体,包括维甲酸X受体(RXR)和维甲酸受体(RAR)是维生素A受体,在肝脏中高表达并通过调节不同的基因来调节重要的生理过程。在这项研究中,我们调查了MTX对肝脏中RXR-α和RAR-α表达的影响以及全反式维甲酸(ATRA)在MTX诱导的肝毒性中的潜在保护作用。将大鼠随机分为五组:用生理盐水,DMSO,MTX(20 mg / kg / IP;单剂量),ATRA(7.5 mg / kg / day,I.P)或MTX和ATRA进行治疗。最后一次ATRA注射后24小时将大鼠处死。解剖出肝脏组织,称重,并进行组织学,免疫组织化学和生化检查。我们的研究结果表明,MTX治疗可导致减少的谷胱甘肽(GSH)含量和超氧化物歧化酶(SOD)活性显着降低,同时ALT,AST和MDA含量也随之升高。此外,MTX显着下调了RXR-alpha和RAR-alpha的表达,并将RXR-alpha的外观更改为非常小的斑点液滴。 ATRA治疗可显着改善MTX对GSH,ALT和MDA的影响。此外,ATRA给药增加了大鼠肝细胞中RXR-α的表达和核易位。总之,我们的研究首次揭示了类维生素A受体可能在MTX诱导的肝毒性中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号